Keebeck Wealth Management Invests $5.54 Million in AbbVie Inc. $ABBV

Keebeck Wealth Management bought a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 22,005 shares of the company’s stock, valued at approximately $5,538,000.

A number of other institutional investors have also added to or reduced their stakes in ABBV. ACT Advisors LLC. increased its position in shares of AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after purchasing an additional 41 shares during the last quarter. Willner & Heller LLC increased its holdings in shares of AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after buying an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC raised its position in shares of AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock valued at $359,000 after buying an additional 43 shares in the last quarter. Fielder Capital Group LLC raised its position in shares of AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock valued at $637,000 after buying an additional 43 shares in the last quarter. Finally, Leslie Global Wealth LLC lifted its holdings in shares of AbbVie by 1.5% during the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company’s stock worth $751,000 after acquiring an additional 44 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted an application to the European Medicines Agency for a subcutaneous induction regimen of Skyrizi in adults with moderately to severely active Crohn’s disease. The filing, supported by Phase 3 AFFIRM data, could broaden Skyrizi’s commercial opportunity and help offset longer-term concerns about AbbVie’s product portfolio. Is AbbVie Undervalued As It Expands Skyrizi In Crohns Disease?
• Positive Sentiment: Analysts remain broadly optimistic about ABBV’s outlook despite the stock’s reported underperformance versus healthcare peers over the past year. The aging population is also viewed as a long-term demand driver for AbbVie’s immunology treatments. How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks
• Neutral Sentiment: AbbVie will present at the Wells Fargo Healthcare Conference on September 9. Investors may look for updates on Skyrizi, Rinvoq and the company’s earnings outlook, but no new financial information was provided in the announcement. AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Trading has been relatively steady as investors await the next earnings update. Recent results provide a supportive backdrop: AbbVie previously exceeded quarterly EPS and revenue expectations, with revenue up year over year. AbbVie Stock Holds Steady as Investors Await the Next Earnings Update
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate for AbbVie, creating a modest headwind for the stock and highlighting the risk that expectations may be difficult to exceed.
• Negative Sentiment: Recent institutional activity was mixed, with Burke & Herbert Bank & Trust selling shares while another manager initiated a position. These 13F changes are historical and have limited near-term significance, but the sale may add slight negative sentiment. Burke and Herbert Bank Sells AbbVie Shares

Wall Street Analyst Weigh In

ABBV has been the topic of a number of research analyst reports. Canaccord Genuity Group increased their target price on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. BNP Paribas Exane upped their price objective on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. HSBC reiterated a “buy” rating and set a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. Royal Bank Of Canada raised their price objective on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. Finally, Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 target price for the company in a research report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $275.95.

AbbVie Price Performance

Shares of AbbVie stock opened at $256.95 on Tuesday. The business’s 50 day simple moving average is $253.20 and its two-hundred day simple moving average is $229.16. The stock has a market capitalization of $453.98 billion, a P/E ratio of 72.58, a price-to-earnings-growth ratio of 0.85 and a beta of 0.30. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the firm posted $2.97 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by company insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.